Enantioselective total synthesis of (+)-ottelione A, (-)-ottelione B, (+)-3-epi-ottelione A and preliminary evaluation of their antitumor activity

Chemistry - A European Journal

Volumn 13, Issue 35, 2007, Pages 9866-9881

  Araki, Hiroshi ^f   Inoue, Munenori ^e   Suzuki, Takeyuki ^d   Yamori, Takao ^c   Kohno, Michiaki ^b   Watanabe, Kazuhiro ^a   Abe, Hideki ^a   Katoh, Tadashi ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e SAGAMI CHEMICAL RESEARCH CENTER   (Japan)

^f TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Antitumor agents; Natural products; Otteliones; Total synthesis; Tubulin polymerization inhibitors

Indexed keywords

ANTICANCER AGENTS; ANTITUMOR AGENTS; COUPLING REACTIONS; NATURAL PRODUCTS; TUBULIN POLYMERIZATION INHIBITORS;

ALDEHYDES; BIOACTIVITY; BIOASSAY; CELL GROWTH; ENANTIOSELECTIVITY;

TUMORS;

ANTINEOPLASTIC AGENT; CYCLOHEXANONE DERIVATIVE; OTTELIONE A; OTTELIONE B; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STEREOISOMERISM; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOHEXANONES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; STEREOISOMERISM; TUBULIN;

EID: 37449003996     PISSN: 09476539     EISSN: 15213765     Source Type: Journal    
DOI: 10.1002/chem.200700789     Document Type: Article

References (38)

1. S.-E. N. Ayyada, A. S. Judd, W. T. Shire, T. R. Hoye, J. Org. Chem. 1998, 65, 8102-8106.
2. Incidentally, ottelionc A (1) was identical to the compound named RPR112378 previously reported in the patent literature by a research group at Rhône-Poulenc Rorer (now Sanofi-Aventis); see: J. Leboul, J. Provost. French patent WO96/00205, 1996 [Chem. Abstr. 1996, 124, 242296].
3. H. Li, X. Qu, Y. Shi, L. Guo, Z. Yuan, Zhongguo Zhongyao Zazhi (Chin. J. Chin. Mater. Med.) 1995, 20, 115-116, 128.
4. For a recent review on microtubule inhibitor for cancer therapy; see: T. Beckers, S. Mahboobi, Drugs of the Future 2003, 28, 767-785.
5. This 4-methylene-2-cyclohexenone system is quite uncommon; see: a) M. E. Jung, H. L. Rayle, Synth. Commun. 1994, 24, 197-203;
6. b) H. Wild, J. Org. Chem. 1994, 59, 2748-2761.
7. C. Combeau, J. Provost, F. Lancelin, Y. Tournoux, F. Prod'homme, F. Herman, F. Lavelle, J. Leboul, M. Vuilhorgne, Mol. Pharm. 2000, 57, 553-563.
8. a) G. Mehta, D. S. Reddy, Chem. Commun. 1999, 2193-2194;
9. b) L. Trembleau, L. Patiny, L. Ghosez. Tetrahedron Lett. 2000, 41, 6377-6381;
10. c) G. Mehta, K. Islam, Synlett 2000, 1473-1475;
11. d) G. Mehta, K. Islam, Org. Lett. 2002, 4, 2881-2884;
12. e) D. L. J. Clive, S. P. Fletcher, Chem. Commun. 2002, 1940-1941;
13. f) H. Araki, M. Inoue, T. Katoh, Synlett 2003, 2401-2404;
14. g) D. L. J. Clive, D. Liu, Tetrahedron Lett. 2005, 46, 5305-5307.
15. G. Mehta, K. Islam, Angew. Chem. 2002, 114, 2502-2504;
16. Angew. Chem. Int. Ed. 2002, 41, 2396-2398.
17. G. Mehta, K. Islam, Tetrahedron Lett. 2003, 44, 6733-6737.
18. H. Araki, M. Inoue, T. Katoh, Org. Lett. 2003, 5, 3903-3906.
19. D. L. J. Clive, D. Liu, Angew. Chem. 2007, 119, 3812-3814;
20. Angew. Chem. Int. Ed. 2007, 46, 3738-3740.
21. a) T. Izuhara, T. Katoh, Tetrahedron Lett. 2000, 41, 7651-7654:
22. b) T. Izuhara, T. Katoh, Org. Lett. 2001, 3, 1653-1656;
23. c) T. Katoh, T. Izuhara, W. Yokota, M. Inoue, K. Watanabe, A. Nobeyama, T. Suzuki, Tetrahedron 2006, 62, 1590-1608.
24. R. Pappo, D. S. Allen, R. U. Lemieux, W. S. Johnson, J. Org. Chem. 1956, 21, 478-479.
25. [10]
26. a) E. J. Corey, R. A. E. Winter, J. Am. Chem. Soc. 1963, 85, 2677-2678;
27. b) E. J. Corey, F. A. Carey, R. A. E. Winter, J. Am. Chem. Soc. 1965, 87, 934-935;
28. c) E. Block, Org. React. 1984, 30, 457-566.
29. [7d] This result can support the formation of 27a-II. equation presented
30. [1]
31. [11]
32. a) T. Yamori, A. Matsunaga, S. Sato, K. Yamazaki, A. Komi, K. Ishizu, I. Mita, H. Edatsugi, Y. Matsuba, K. Takezawa, O. Nakanishi, H. Kohno, Y. Nakajima, H. Komatsu, T. Andoh, T. Tsuruo, Cancer Res. 1999, 59, 4042-4049;
33. b) S. Dan, T. Tsunoda, O. Kitahara, R. Yanagawa, H. Zembutsu, T. Katagiri, K. Yamazaki, Y. Nakamura, T. Yamori, Cancer Res. 2002, 62, 1139-1147;
34. c) T. Yamori, Cancer Chemother. Pharmacol. 2003, 52 (Suppl. 1), 74-79.
35. a) K. D. Pauli, R. H. Shoemaker, L. Hodes, A. Monks, D. A. Scudiero, L. Rubinstein, J. Plowman, M. R. Boyd, J. Natl. Cancer Inst. 1989, 81, 1088-1092;
36. b) A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, J. Natl. Cancer Inst. 1991, 83, 757-866.
37. a) S. Yaguchi, Y. Fukui, I. Koshimizu, H. Yoshimi, T. Matsuno, H. Gouda, S. Hirono, K. Yamazaki, T. Yamori, J. Natl. Cancer Inst. 2006, 98, 545-556.
38. M. Kohno, K. Watanabe, S. Tanimura, Gan to Kagaku Ryoho (Jpn. J. Cancer Chemother.), 2004, 31, 501-506.